biostudies-literatureChae YKBristol Myers Squibb Foundation (BMSF)Center for Cancer Research (CCR)NCI NIH HHSBristol Myers Squibb FoundationCenter for Cancer Research5593-5600https://www.ebi.ac.uk/biostudies/studies/S-EPMC11737520biostudies-literatureUnknown30(24)<h4>Purpose</h4>The role of dual checkpoint inhibition (ipilimumab at 1 mg/kg intravenously every 6 weeks and nivolumab at 240 mg intravenously every 2 weeks) in advanced rare/ultrarare nonepithelial ovarian cancers is yet to be explored.<h4>Patients and methods</h4>Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumor is a prospective, multicenter (1,016 US sites), multicohort, single-arm phase II trial conducted through the Early Therapeutics and Rare Cancer SWOG/NCI Committee, assessing ipilimumab (anti-CTLA-4; 1 mg/kg every 6 weeks) and nivolumab (anti-PD-1; 240 mg every 2 weeks) in adults with advanced nonepithelial ovarian cancers who lack beneficial standard therapy. The primary outcome was overall response rate [ORR; complete response (CR)/partial response (PR)]; secondary outcomesClinical cancer research : an official journal of the American Association for Cancer ResearchSWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.PMC11737520U10CA180820U10 CA180819U10180821UG1CA189872UG1 CA189954U10 CA180820U10CA180819UG1 CA189872UG1CA233198U10 CA180868U10 CA180821U10 CA180888UG1CA189954U10CA180868UG1 CA233320U10CA180888UG1CA233320UG1 CA233198McLeod CMAdra NRyan CWEllerton JALea JRobinson WRWilkinson KJLopez GChae YKBlanke CDPatel SPOthus MWalter ASharon EPoklepovic AThomes Pepin JSchallenkamp JMKim HSStreicher HChung LIRampurwala MMKurzrock RWhitman-Purves EMChen HXAlden MAppleman LJfalseSWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.<h4>Purpose</h4>The role of dual checkpoint inhibition (ipilimumab at 1 mg/kg intravenously every 6 weeks and nivolumab at 240 mg intravenously every 2 weeks) in advanced rare/ultrarare nonepithelial ovarian cancers is yet to be explored.<h4>Patients and methods</h4>Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumor is a prospective, multicenter (1,016 US sites), multicohort, single-arm phase II trial conducted through the Early Therapeutics and Rare Cancer SWOG/NCI Committee, assessing ipilimumab (anti-CTLA-4; 1 mg/kg every 6 weeks) and nivolumab (anti-PD-1; 240 mg every 2 weeks) in adults with advanced nonepithelial ovarian cancers who lack beneficial standard therapy. The primary outcome was overall response rate [ORR; complete response (CR)/partial response (PR)]; secondary outcomes2024-01-01T00:00:00Z2024 Dec2026-06-01T06:26:48.286Z2026-04-08T09:53:02.351ZS-EPMC117375203941769210.1158/1078-0432.CCR-24-060610.1158/1078-0432.ccr-24-0606